Refractory hematologic cancer
MONDO:0004111A hematologic malignancy that is resistant to treatment.
Also known as: refractory hematologic cancer, refractory hematologic malignancy
2139 clinical trials for this condition and its sub-types, 62 tagged with Refractory hematologic cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Refractory hematologic cancer
-
Refractory plasma cell neoplasm 228 trials
-
Refractory hairy cell leukemia 9 trials
-
2 sub-types
-
Refractory cytopenia of childhood 0 trials
-
Last-resort leukemia combo shows early promise in tiny trial
Disease control CompletedThis early-phase study tested a combination of two drugs, venetoclax and omacetaxine, in 6 adults with acute myeloid leukemia (AML) whose cancer had stopped responding to venetoclax-based treatments. The main goal was to find the safest dose of omacetaxine when given with venetoc…
Phase 1 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy shows promise for hard-to-treat childhood cancers
Disease control CompletedThis early-stage study tested a mix of two drugs (pembrolizumab and decitabine) plus targeted radiation in 22 children and young adults whose solid tumors or lymphoma had returned or stopped responding to treatment. The main goals were to see if the combination was safe and toler…
Early phase 1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New antibody drug tested in patients with relapsed blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for kids with tough cancers: experimental combo shows promise
Disease control CompletedThis early-phase study tested a three-drug combination (carfilzomib, cyclophosphamide, and etoposide) in 4 children whose solid tumors or leukemias had come back or didn't respond to standard treatment. The main goal was to find the safest dose and identify side effects. The stud…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC